However, if your logo-creating needs are simple, Hatchful’s offering could be for you. After running through the process, you'll come out the other side with high-resolution images suitable for ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

However, today, Wells Fargo maintained a Hold rating on Biogen (NASDAQ: BIIB). The company has a one-year high of $238.00 and a one-year low of $128.51. Currently, Biogen has an average volume of ...

However, on the same day, Wells Fargo maintained a Hold rating on Biogen (NASDAQ: BIIB). The company has a one-year high of $238.00 and a one-year low of $128.51. Currently, Biogen has an average ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00. The company has ...

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

stating it "significantly undervalues" the company and does not serve shareholders' best interests. Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

The neuro-focused biotech is “making changes” to its research team to “reinvigorate the company's drug discovery capabilities and support long-term sustainable growth,” a Biogen ...